Navigation Links
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
Date:11/2/2009

, are currently in preparation and will be presented at forthcoming scientific conferences.

Juergen Engel, Ph.D., AEterna Zentaris President and Chief Executive Officer stated, "We are pleased with the progress of this project. The successful completion of the recruitment and treatment phase and the apparent activity in this difficult group of cancer patients is encouraging. This is the basis we were looking for, in order to take the next steps in the further development of AEZS-108 in gynaecological cancers and possibly also in prostate cancer."

About the AEZS-108 Phase 2 Program

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

In a Phase 2 study program entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", patients with tumors expressing LHRH receptors are administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is 6, 3-week cycles. Study AGO-GYN-5 is performed with 14 centers of the German Gynaecological Oncology Working Group (AGO; www.ago-ovar.de), in cooperation with 3 clinical sites in Europe.

The program was planned to include up to 82 patients, up to 41 with a diagnosis of platinum-resistant and taxane-pretreated ovarian cancer, and up to 41 with disseminated endometrial cancer. For both indications, pati
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... associated with a small increased risk of prostate cancer, ... cancer according to a new study from Harvard School ... association remained even among men who received regular PSA ... be explained by diagnostic bias. It is the largest ... the link between vasectomy and prostate cancer. , The ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... conditions are likely to change their preferences for receiving ... to new findings. The study, which will ... in Amsterdam today (26 September 2011), suggests that different ... but this will often go unnoticed by their healthcare ...
... new study has shown that people with chronic obstructive ... are at a serious risk of developing cardiovascular disease. ... September 2011) at the European Respiratory Society,s Annual Congress ... lung function should be routinely screened for cardiovascular disease, ...
... a phase III clinical trial have shown that ... women with advanced breast cancer resistant to hormonal ... European Multidisciplinary Cancer Congress [1] that women treated ... an improved progression-free survival of nearly seven months ...
... Reporter , FRIDAY, Sept. 23 (HealthDay News) -- Many studies ... a day is heart-healthy, and much of the benefit has ... red wine called polyphenols. But a new Dutch study ... not lower blood pressure after all. Study author ...
... trial comparing tamoxifen with the aromatase inhibitor letrozole ... of time and continues to prevent breast cancer ... post-menopausal women with hormone receptor-positive early breast cancer. ... 2011 European Multidisciplinary Cancer Congress [1], in Stockholm ...
... The Netherlands: Belly fat, known clinically as central obesity, has ... study. The findings, which will be presented at the ... 2011), have shown central obesity as a risk factor for ... a number of health effects, such as diabetes and heart ...
Cached Medicine News:Health News:Study shows decisions over life-sustaining treatment are likely to change 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy 2Health News:Antioxidants Not Behind Red Wine's Healthy Effect on Heart: Study 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4Health News:'Belly fat' linked to development of asthma 2
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... May 18, 2011 The Consumer Healthcare Products ... acetaminophen medicines for children, applauds the U.S. Food ... and caregivers give their children the right amount ... Committee and Pediatric Advisory Committee recommended enhancing the ...
... Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... neuro-otologic, vestibular and neurological testing, said today that ... control and analysis software. Clinical specialists ... conduct vestibular, oculomotor and optokinetic tests to detect ...
Cached Medicine Technology:OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software 2
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 100 mg/dL (35.6 ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
Medicine Products: